Japan, July 14 -- DAIICHI SANKYO CO LTD has got intellectual property rights for 'COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR.' Other related details are as follows:
Application Number: JP,2024-043043
Category (FI): A61K45/00,A61K47/68,A61K31/4745,A61P35/00,A61P43/00,121,A61K39/395@D,A61K39/395@N,A61K31/357,A61K31/337,C12N15/13,A61K39/395@T
Stage: PROBLEM TO BE SOLVED: To provide a pharmaceutical composition such that a specific antibody-drug conjugate and a tubulin inhibitor are administered in combination, and/or a method of treatment.SOLUTION: The present invention provides a pharmaceutical composition such that an antibody-drug conjugate in which a drug-linker represented by the following formula (where A represents a connecting position to an antibody) is conjugated to an antibody via a thioether bond, and a tubulin inhibitor are administered in combination, and a method of treatment.SELECTED DRAWING: Figure 9 (Grant)
Filing Date: March 19, 2024
Publication Date: June 4, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
